Selexis S.A.

Our timelines for cell line development and our innovation are unparalleled. This is our focus, and this is why we are the best at it. Ultimately, we help companies bring drugs to patients faster and more cost-effectively.

From our laboratories in Geneva, we primarily develop technologies for Chinese hamster ovary (CHO) cells, which support biopharmaceutical companies worldwide in the development of therapeutic biologics. The term biologics refers to a wide range of drugs that are produced in living systems. Selexis supports its partners to realize the full potential of their biotherapeutic programs and reach patients faster with new treatments. In 2020, our partners' clinical programs using our Selexis SUREtechnology™ platform grew to 136. We celebrated two marketed products from our partners, bringing our total to eight marketed products in the areas of oncology and autoimmune diseases.

The Selexis SUREtechnology Platform™ improves the way mammalian cells are used in the discovery, development and production of recombinant proteins and drugs.